iNtRON Biotechnology, Inc.

KOSDAQ 048530.KQ

iNtRON Biotechnology, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 17.54

iNtRON Biotechnology, Inc. Price to Sales Ratio (P/S) is 17.54 on January 14, 2025, a -33.67% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

iNtRON Biotechnology, Inc. 52-week high Price to Sales Ratio (P/S) is 26.44 on January 15, 2024, which is 50.76% above the current Price to Sales Ratio (P/S).
iNtRON Biotechnology, Inc. 52-week low Price to Sales Ratio (P/S) is 13.70 on December 09, 2024, which is -21.87% below the current Price to Sales Ratio (P/S).
iNtRON Biotechnology, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 20.07.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

KOSDAQ: 048530.KQ

iNtRON Biotechnology, Inc.

CEO	Mr. Seong-Jun Yoon
IPO Date	Jan. 26, 2011
Location	South Korea
Headquarters	137, Sagimakgol-ro
Employees	76
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

iNtRON Biotechnology, Inc. develops biopharmaceuticals for the prevention and treatment of human diseases worldwide. It develops bacteriophage and endoricin drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.

Key trends

Past 5 years